Log in

Invivo Therapeutics News Headlines (NASDAQ:NVIV)

$7.12
-0.04 (-0.56 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$6.73
Now: $7.12
$7.80
50-Day Range
$0.18
MA: $0.69
$8.10
52-Week Range
$3.69
Now: $7.12
$52.14
Volume159,270 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Invivo Therapeutics (NASDAQ NVIV) News Headlines

Source:
DateHeadline
InVivo Therapeutics Holdings CorpInVivo Therapeutics Holdings Corp
www.bloomberg.com - February 16 at 12:58 PM
2019 Update of InVivo Therapeutics Corp - Product Pipeline Analysis - ResearchAndMarkets.com2019 Update of InVivo Therapeutics Corp - Product Pipeline Analysis - ResearchAndMarkets.com
www.businesswire.com - February 13 at 2:12 PM
Contrasting Delcath Systems (OTCMKTS:DCTH) and Invivo Therapeutics (OTCMKTS:NVIV)Contrasting Delcath Systems (OTCMKTS:DCTH) and Invivo Therapeutics (OTCMKTS:NVIV)
www.americanbankingnews.com - February 6 at 6:45 PM
Invivo Therapeutics Stock Set to Reverse Split on Wednesday, February 12th (NASDAQ:NVIV)Invivo Therapeutics Stock Set to Reverse Split on Wednesday, February 12th (NASDAQ:NVIV)
www.americanbankingnews.com - February 4 at 11:02 AM
InVivo to reverse split shares 1:30InVivo to reverse split shares 1:30
seekingalpha.com - February 3 at 5:57 PM
InVivo Therapeutics Announces Reverse Stock SplitInVivo Therapeutics Announces Reverse Stock Split
finance.yahoo.com - February 3 at 5:57 PM
InVivo Therapeutics Announces Closing of Public Offering of Common StockInVivo Therapeutics Announces Closing of Public Offering of Common Stock
finance.yahoo.com - November 22 at 6:25 PM
InVivo Therapeutics Announces Pricing of Public Offering of Common StockInVivo Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - November 21 at 12:07 PM
InVivo Therapeutics Announces Proposed Public Offering of Common StockInVivo Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - November 18 at 12:47 PM
InVivo Therapeutics Announces Appointment of Robert Rosenthal to Board of DirectorsInVivo Therapeutics Announces Appointment of Robert Rosenthal to Board of Directors
finance.yahoo.com - November 12 at 9:43 AM
Biotech CEO found guilty of defrauding investorsBiotech CEO found guilty of defrauding investors
finance.yahoo.com - October 29 at 1:52 PM
InVivo Therapeutics Announces Publication of CONTEMPO Registry Study Data in Peer-Reviewed Journal Spinal CordInVivo Therapeutics Announces Publication of CONTEMPO Registry Study Data in Peer-Reviewed Journal Spinal Cord
finance.yahoo.com - July 16 at 8:48 AM
InVivo postpones shareholder meetingInVivo postpones shareholder meeting
seekingalpha.com - July 12 at 8:30 AM
InVivo Therapeutics Announces Postponement of Annual MeetingInVivo Therapeutics Announces Postponement of Annual Meeting
finance.yahoo.com - July 12 at 8:30 AM
InVivo Therapeutics Announces Adjournment of Annual MeetingInVivo Therapeutics Announces Adjournment of Annual Meeting
finance.yahoo.com - June 14 at 11:08 AM
Five things you need to know today, and one small step for the mediaFive things you need to know today, and one small step for the media
www.bizjournals.com - May 30 at 8:34 AM
Enrollment underway in SCI study of InVivos Neuro-Spinal ScaffoldEnrollment underway in SCI study of InVivo's Neuro-Spinal Scaffold
seekingalpha.com - May 29 at 6:53 PM
Bob Langer-founded device-maker InVivo starts new trial after patient deathsBob Langer-founded device-maker InVivo starts new trial after patient deaths
finance.yahoo.com - May 29 at 6:53 PM
InVivo Therapeutics Announces Enrollment of First Two Patients into the INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord InjuryInVivo Therapeutics Announces Enrollment of First Two Patients into the INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury
finance.yahoo.com - May 29 at 8:29 AM
InVivo up 2% premarket on new Neuro-Spinal Scaffold dataInVivo up 2% premarket on new Neuro-Spinal Scaffold data
seekingalpha.com - April 17 at 7:22 PM
InVivo Therapeutics Announces Presentation of Twelve-Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord InjuryInVivo Therapeutics Announces Presentation of Twelve-Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury
finance.yahoo.com - April 17 at 7:22 PM
InVivo Therapeutics Reports 2018 Year-end Financial Results and Provides Business UpdateInVivo Therapeutics Reports 2018 Year-end Financial Results and Provides Business Update
www.marketwatch.com - April 1 at 8:34 AM
Form 424B3 INVIVO THERAPEUTICS HOLD - StreetInsider.comForm 424B3 INVIVO THERAPEUTICS HOLD - StreetInsider.com
www.streetinsider.com - January 16 at 5:50 PM
InVivo Therapeutics appoints new finance chiefInVivo Therapeutics appoints new finance chief
seekingalpha.com - January 14 at 10:18 AM
InVivo Therapeutics Announces Appointment of Richard Christopher as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)InVivo Therapeutics Announces Appointment of Richard Christopher as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - January 14 at 10:18 AM
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel